DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneMPSvoice.com | ||
To unsubscribe from these emails, click here |
Mucopolysaccharidosis I (MPS I) Registry
study id #: NCT00144794
condition: Mucopolysaccharidosis I (MPS I)
status: Recruiting
purpose:The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care
results: https://clinicaltrials.gov/ct2/show/results/NCT00144794
last updated: February 26, 2022
start date: November 20, 2003
estimated completion: January 31, 2034
last updated: December 9, 2021
size / enrollment: 1500
study description: The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact:
In Asia-Pacific - Vivian Liu, +65-6431-2548, [email protected]
In Europe - +31-35-699-1232, [email protected]
In Latin America - +617-591-5500, [email protected]
In North America - +617-591-5500, [email protected]
primary outcomes:
- To evaluate the long-term effectiveness of Aldurazyme
- Approximately 17 Years
inclusion criteria:
• Eligible Sexes: all
All patients with a confirmed diagnosis of MPS I are eligible for inclusion. Confirmed diagnosis is defined as: A. documented biochemical evidence of a deficiency in alpha (a)-L-iduronidase enzyme activity and/or B. mutation(s) in the gene coding for a-L-iduronidase, or measurable clinical signs and symptoms of MPS I
For all patients there should be a completed patient authorization form
exclusion criteria: Criteria:
No exclusion criteria for participation in the MPS I Registry. NOTE: Registry participation does not exclude participation in other clinical studies.
sponsor: Genzyme, a Sanofi Company
contacts: For Site Information, Send An Email With Site Number To, [email protected]
investigators: Medical Monitor,Genzyme, A Sanofi Company
trial center locations: United States,Argentina,Australia,Belgium,Brazil,Canada,Chile,Colombia,Croatia,Czechia,Denmark,Egypt,France,Germany,Hungary,India,Indonesia,Ireland,Italy,Japan,Korea, Republic of,Kuwait,Lebanon,Malaysia,Netherlands,Pakistan,Philippines,Poland,Portugal,Romania,Russian Federation,Saudi Arabia,Singapore,Slovakia,Sweden,Taiwan,Thailand,United Arab Emirates,United Kingdom,Vietnam
-
United States, Arizona
Investigational Site Number :840003
-
United States, Arkansas
Investigational Site Number :840109
-
United States, California
Investigational Site Number :840068
-
United States, California
Investigational Site Number :840108
-
United States, California
Investigational Site Number :840082
-
United States, California
Investigational Site Number :840029
-
United States, California
Investigational Site Number :840074
-
United States, California
Investigational Site Number :840022
-
United States, California
Investigational Site Number :840010
-
United States, California
Investigational Site Number :840117
-
United States, California
Investigational Site Number :840007
-
United States, California
Investigational Site Number :840051
-
United States, Colorado
Investigational Site Number :840069
-
United States, Connecticut
Investigational Site Number :840047
-
United States, District Of Columbia
Investigational Site Number :840067
-
United States, Florida
Investigational Site Number :840083
-
United States, Florida
Investigational Site Number :840112
-
United States, Florida
Investigational Site Number :840006
-
United States, Florida
Investigational Site Number :840017
-
United States, Georgia
Investigational Site Number :840060
-
United States, Illinois
Investigational Site Number :840011
-
United States, Illinois
Investigational Site Number :840079
-
United States, Indiana
Investigational Site Number :840027
-
United States, Iowa
Investigational Site Number :840032
-
United States, Kentucky
Investigational Site Number :840030
-
United States, Louisiana
Investigational Site Number :840120
-
United States, Maryland
Investigational Site Number :840044
-
United States, Massachusetts
Investigational Site Number :840062
-
United States, Massachusetts
Investigational Site Number :840093
-
United States, Massachusetts
Investigational Site Number :840002
-
United States, Michigan
Investigational Site Number :840107
-
United States, Michigan
Investigational Site Number :840066
-
United States, Minnesota
Investigational Site Number :840114
-
United States, Minnesota
Investigational Site Number :840076
-
United States, Missouri
Investigational Site Number :840100
-
United States, Nebraska
Investigational Site Number :840084
-
United States, Nevada
Investigational Site Number :840008
-
United States, New Jersey
Investigational Site Number :840101
-
United States, New Jersey
Investigational Site Number :840099
-
United States, New Jersey
Investigational Site Number :840016
-
United States, New Jersey
Investigational Site Number :840057
-
United States, New York
Investigational Site Number :840102
-
United States, New York
Investigational Site Number :840040
-
United States, New York
Investigational Site Number :840110
-
United States, New York
Investigational Site Number :840105
-
United States, New York
Investigational Site Number :840052
-
United States, North Carolina
Investigational Site Number :840037
-
United States, Ohio
Investigational Site Number :840041
-
United States, Ohio
Investigational Site Number :840119
-
United States, Ohio
Investigational Site Number :840091
-
United States, Ohio
Investigational Site Number :840094
-
United States, Oregon
Investigational Site Number :840080
-
United States, Pennsylvania
Investigational Site Number :840089
-
United States, Pennsylvania
Investigational Site Number :840034
-
United States, Pennsylvania
Investigational Site Number :840023
-
United States, Rhode Island
Investigational Site Number :840053
-
United States, South Carolina
Investigational Site Number :840055
-
United States, Texas
Investigational Site Number :840058
-
United States, Utah
Investigational Site Number :840092
-
United States, Virginia
Investigational Site Number :840078
-
United States, Virginia
Investigational Site Number :840072
-
United States, Washington
Investigational Site Number :840028
-
United States, Washington
Investigational Site Number :840059
-
United States, Washington
Investigational Site Number :840115
-
United States, Wisconsin
Investigational Site Number :840054
-
Argentina
Investigational Site Number :153130
-
Argentina, Buenos Aires
Investigational Site Number :153032
-
Australia, New South Wales
Investigational Site Number :151069
-
Australia, Queensland
Investigational Site Number :152096
-
Belgium
Investigational Site Number :150517
-
Belgium
Investigational Site Number :150944
-
Belgium
Investigational Site Number :151668
-
Belgium
Investigational Site Number :154008
-
Brazil
Investigational Site Number :076002
-
Brazil
Investigational Site Number :076004
-
Brazil, Rio Grande Do Sul
Investigational Site Number :076001
-
Brazil, São Paulo
Investigational Site Number :076007
-
Canada, Alberta
Investigational Site Number :124002
-
Canada, Alberta
Investigational Site Number :124014
-
Canada, British Columbia
Investigational Site Number :124011
-
Canada, Manitoba
Investigational Site Number :124019
-
Canada, New Brunswick
Investigational Site Number :124022
-
Canada, Ontario
Investigational Site Number :124006
-
Canada, Ontario
Investigational Site Number :124021
-
Canada, Quebec
Investigational Site Number :124001
-
Canada, Quebec
Investigational Site Number :124018
-
Chile
Investigational Site Number :152001
-
Chile
Investigational Site Number :152003
-
Colombia
Investigational Site Number :170001
-
Croatia
Investigational Site Number :1910001
-
Czechia
Investigational Site Number :150659
-
Denmark
Investigational Site Number :151229
-
Egypt
Investigational Site Number :818001
-
Egypt
Investigational Site Number :818002
-
France
Investigational Site Number :250001
-
France
Investigational Site Number :250002
-
France
Investigational Site Number :250003
-
France
Investigational Site Number :250004
-
France
Investigational Site Number :250005
-
France
Investigational Site Number :250006
-
Germany
Investigational Site Number :150031
-
Germany
Investigational Site Number :151368
-
Hungary
Investigational Site Number :154654
-
India
Investigational Site Number :3560004
-
India
Investigational Site Number :356001
-
India
Investigational Site Number :356002
-
India
Investigational Site Number :356003
-
Indonesia
Investigational Site Number :360001
-
Ireland
Investigational Site Number :153020
-
Italy
Investigational Site Number :380001
-
Italy
Investigational Site Number :380002
-
Italy
Investigational Site Number :380003
-
Italy
Investigational Site Number :380004
-
Italy
Investigational Site Number :380005
-
Italy
Investigational Site Number :380006
-
Italy
Investigational Site Number :380007
-
Italy
Investigational Site Number :380008
-
Italy
Investigational Site Number :380009
-
Japan, Kochi
Investigational Site Number :392102
-
Japan, Tokyo
Investigational Site Number :392101
-
Korea, Republic Of
Investigational Site Number :151149
-
Korea, Republic Of
Investigational Site Number :153178
-
Korea, Republic Of
Investigational Site Number :153180
-
Korea, Republic Of
Investigational Site Number :153191
-
Korea, Republic Of
Investigational Site Number :153192
-
Korea, Republic Of
Investigational Site Number :153196
-
Korea, Republic Of
Investigational Site Number :153212
-
Korea, Republic Of
Investigational Site Number :153222
-
Korea, Republic Of
Investigational Site Number :153225
-
Korea, Republic Of
Investigational Site Number :154148
-
Korea, Republic Of, Gyeongsangnam-do
Investigational Site Number :154286
-
Kuwait
Investigational Site Number :154225
-
Lebanon
Investigational Site Number :4220004
-
Malaysia
Investigational Site Number :458001
-
Malaysia
Investigational Site Number :458002
-
Netherlands
Investigational Site Number :151171
-
Netherlands
Investigational Site Number :152029
-
Pakistan
Investigational Site Number :154264
-
Pakistan
Investigational Site Number :154266
-
Philippines
Investigational Site Number :608001
-
Poland
Investigational Site Number :150575
-
Portugal
Investigational Site Number :6200002
-
Romania
Investigational Site Number :154177
-
Russian Federation
Investigational Site Number :643001
-
Russian Federation
Investigational Site Number :643002
-
Saudi Arabia
Investigational Site Number :682001
-
Saudi Arabia
Investigational Site Number :682004
-
Singapore
Investigational Site Number :702001
-
Slovakia
Investigational Site Number :703001
-
Sweden
Investigational Site Number :7520001
-
Taiwan
Investigational Site Number :151179
-
Taiwan
Investigational Site Number :151181
-
Taiwan
Investigational Site Number :151182
-
Taiwan
Investigational Site Number :151500
-
Taiwan
Investigational Site Number :151534
-
Taiwan
Investigational Site Number :152152
-
Taiwan
Investigational Site Number :152153
-
Taiwan
Investigational Site Number :152244
-
Taiwan
Investigational Site Number :152246
-
Taiwan
Investigational Site Number :152321
-
Taiwan
Investigational Site Number :153158
-
Taiwan
Investigational Site Number :153248
-
Taiwan
Investigational Site Number :154093
-
Thailand
Investigational Site Number :764001
-
Thailand
Investigational Site Number :764002
-
Thailand
Investigational Site Number :764003
-
Thailand
Investigational Site Number :764004
-
Thailand
Investigational Site Number :764005
-
United Arab Emirates
Investigational Site Number :TBC
-
United Kingdom
Investigational Site Number :150303
-
United Kingdom
Investigational Site Number :150455
-
United Kingdom
Investigational Site Number :151123
-
United Kingdom
Investigational Site Number :151646
-
United Kingdom
Investigational Site Number :152156
-
United Kingdom
Investigational Site Number :152287
-
United Kingdom
Investigational Site Number :152361
-
United Kingdom
Investigational Site Number :154240
-
Vietnam
Investigational Site Number :154212
-
Vietnam
Investigational Site Number :704002
-
educationDamage of the Cardiovascular System in Lysosomal Storage Disease – MucopolysaccharidosisThe analysis of literature data reflecti...
-
educationMucopolysaccharidosis II (MPS II) in a Free-Living Kaka (Nestor Meridionalis) in New ZealandA lysosomal storage disease, identified ...
-
educationThe Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
-
videos & visualsX-Linked Recessive Inheritance Pattern in MPS II (Hunter Syndrome)https://www.onempsvoice.com/wp-content/u...
-
educationHunter Syndrome: OverviewHunter syndrome is a very rare, inherite...
-
educationIssues of COVID-19-Related Distance Learning for Children With Neuronopathic MucopolysaccharidosesThe COVID-19 pandemic has impacted the e...
-
people & placesWalla Al-Hertani, MD, MS, FRCPC, FCCMG, FACMGDr. Walla Al-Hertani is a Medical Bioche...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email